113531-09-2

Upstream product

• 128218-35-9 3-<(1-phenylethyl)amino>propanol 

Downstream Products

• 73834-60-3 2(S)--3-<(S)-α-methylbenzyl>-1,3,2-oxazaphosphorinane 2-oxide 
• 73837-99-7 2(S)--3-<(R)-α-methylbenzyl>-1,3,2-oxazaphosphorinane 2-oxide 
• 164165-46-2 (S_CS_P)-2-anilino-3-(α-methylbenzyl)-1,3,2λ⁵-oxazaphosphorinane 2-oxide 
• 58028-72-1 2(S)--3-<(S)-α-methylbenzyl>-1,3,2-oxazaphosphorinane 2-oxide 
• 433709-05-8 2-chloro-N-[2-oxo-3-(1-phenyl-ethyl)-2λ⁵-[1,3,2]oxazaphosphinan-2-yl]-acetamide 
• 433709-06-9 C₁₃H₁₈⁽²⁾H₂ClN₂O₂P 

Relevant academic research and scientific papers

Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue

Deutero-substituted (α,α,α′,α′-tetradeuterated) derivatives of ifosfamide (IF-d4) and its bromo analogue were synthesised. In vitro metabolic studies showed that microsomal hydroxylation of IF-d4 is slower than for unlabelled compound, suggesting that kinetic isotope effect operates during those transformations. At the same time deutero-substituted derivatives are more active against L1210 leukaemia in mice than unlabelled compounds, suggesting a negative role of side-chain hydroxylation metabolic pathways in the anticancer activity of ifosfamide and its analogues.